Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1999
Business Overview: Myriad Genetics focuses on research and development, collaborative research agreements, and operating a genetic testing laboratory. The company has been unprofitable since inception, relying on funding from collaborations with major pharmaceutical companies (Novartis, Bayer, Schering, Monsanto) and revenue from genetic testing services (e.g., BRACAnalysis, CardiaRisk).
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 1999 | Nine Months Ended Mar 31, 1999 |
|---|---|---|
| Total Revenues | $7,062,115 | $18,369,572 |
| Net Loss | ($2,177,974) | ($7,730,736) |
| Loss Per Share (Basic/Diluted) | ($0.23) | ($0.82) |
| Cash and Cash Equivalents | $8,334,758 | $8,334,758 (Ending Balance) |
| Net Cash Used in Operating Activities | N/A | ($10,294,215) |
| Accumulated Deficit | ($41,675,162) | ($41,675,162) |
Liquidity: As of March 31, 1999, the company held $8.3 million in cash and cash equivalents and $34.8 million in total marketable investment securities. Management anticipates existing capital resources will be adequate for at least the next two years.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 24% to $7.1 million for the quarter compared to $5.7 million in the prior year quarter. This was driven by a 164% increase in genetic testing revenue ($1.49 million vs. $0.57 million) and a 9% increase in research revenue.
- Expense Trends: Research and development expenses rose 13% to $6.14 million due to expanded collaboration activities. Conversely, selling, general, and administrative (SG&A) expenses decreased 18% to $2.70 million, attributed to the completion of sales force start-up costs incurred in the prior year.
- Profitability: The net loss narrowed to $2.18 million for the quarter from $2.65 million in the prior year quarter, despite higher operating expenses, due to significant revenue growth.
- Cash Position: Cash and cash equivalents decreased by $6.26 million over the nine-month period, primarily due to net cash used in operating activities ($10.3 million) and capital expenditures, partially offset by proceeds from the sale of equipment and investment activities.
Outlook, Risks, and Management Commentary
- Future Outlook: Management expects to incur losses for at least the next several years due to the expansion of R&D programs, staffing costs, and facility expansion. The company intends to raise funds when conditions are favorable to meet substantial future capital requirements.
- New Subsidiary: In April 1999, the company formed Myriad Pharmaceuticals, Inc., a wholly-owned subsidiary to develop therapeutic lead compounds using the company's ProNet protein interaction technology.
- Year 2000 Issue: The company is in Phase II of its Year 2000 readiness analysis. While management does not expect a material effect on operations, risks include potential system failures, delays in invoicing or receiving payments, and interruptions to R&D efforts if modifications are not completed timely.
- Collaborative Agreements: Significant revenue potential exists through milestone payments and royalties from agreements with Novartis, Bayer, Schering, and Monsanto. However, there is no assurance that additional collaborative relationships will be secured on acceptable terms.
Key Facts for Investor Verification
- Sustainability of Losses: Verify the company's ability to fund operations for the projected two-year runway given the $10.3 million cash burn from operations in the first nine months of the fiscal year.
- Revenue Recognition: Confirm the proportionality of research revenue recognition to incurred costs under collaborative agreements, as this drives a significant portion of total revenue.
- Genetic Testing Growth: Assess the sustainability of the 164% year-over-year growth in genetic testing revenue and the associated increase in trade receivables ($744,703 increase).
- Year 2000 Compliance: Monitor the completion of Phase II testing and the implementation of contingency plans to mitigate operational risks associated with the Year 2000 transition.
- Capital Requirements: Evaluate the necessity and timing of future equity or debt financing to support the new pharmaceutical subsidiary and ongoing R&D expansion.